摘要
Hepatitis B virus infection represents a major global public health challenge.1 Chronic hepatitis B(CHB)virus infection is a leading cause of liver fibrosis,a key pathological process that drives the progression of chronic liver disease to cirrhosis.Current clinical guidelines recommend the immediate initiation of antiviral therapy upon detection of significant liver fibrosis in patients with CHB.2–4 Early-stage fibrosis may be reversible with effective antiviral treatment,whereas advanced fibrosis or cirrhosis shows limited reversibility despite therapy.5 As such,early identification and staging of liver fibrosis,followed by timely antiviral intervention,are crucial for optimizing the management of CHB and improving longterm patient outcomes.
基金
the National Key Research and Development Program of China(2022YFC2304500)
the Zhejiang Province Natural Science Foundation of China(LTGY24H160016).
